|
|
 Previous Article | Table of Contents | Next Article 
SUP-HD1: a new Hodgkin's disease-derived cell line with lymphoid features
produces interferon-gamma [see comments]
L Naumovski, PJ Utz, SK Bergstrom, R Morgan, A Molina, JJ Toole, BE Glader, P McFall, LM Weiss and R Warnke
Department of Pediatrics, Stanford University School of Medicine, CA.
A new cell line, SUP-HD1, was established from the pleural effusion of a
patient with nodular sclerosing Hodgkin's disease (NSHD). The SUP-HD1 cells
had the characteristic morphology of Reed-Sternberg cells and contained
acid phosphatase and nonspecific esterase. The cells lacked the
Epstein-Barr virus (EBV) genome and reacted with monoclonal antibodies
(MoAbs) against CD15 (Leu-M1), CD25 (Tac), CD71 (OKT9), Ki67, and HLA-Dr.
However, the SUP-HD1 cells were nonreactive with MoAbs that specifically
identify T lymphocytes, B lymphocytes, and macrophage/myeloid cells.
Karyotype analysis of the cell line showed clonal abnormalities involving
1p13, 7p15, 8q22, and 11q23, chromosomal locations, at which breakpoints
have been reported in HD. Southern blot analysis demonstrated rearrangement
of the immunoglobulin heavy chain and kappa light chain genes as well as
the gene for the beta chain of the T-cell receptor (TCR). Transcriptional
analysis showed expression of RNAs for kappa light chain, interferon-gamma
(IFN-gamma), and interleukin-2 receptor (IL-2R) but not IL-2. The SUP-HD1
cells lacked cytoplasmic and surface immunoglobulin heavy chain, but a
small amount of cytoplasmic kappa light chain was detected. The presence of
nuclear factor kappa B (NF kappa B), a B-lymphocyte-associated
transcription factor, was demonstrated in stimulated and unstimulated
cells. In addition, the SUP-HD1 cell line, produced IFN-gamma, a
T-lymphocyte- associated lymphokine. Based on these data, the SUP-HD1 cells
appear to be aberrant lymphocytes with characteristics of both activated B
and T lymphocytes. Elaboration of lymphokines such as IFN-gamma by the
malignant cells may represent one explanation for the unique clinical and
pathologic features of HD.
Volume 74,
Issue 8,
pp. 2733-2742,
12/01/1989
Copyright © 1989 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Miyanaga, A. Gemma, R. Noro, K. Kataoka, K. Matsuda, M. Nara, T. Okano, M. Seike, A. Yoshimura, A. Kawakami, et al.
Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
Mol. Cancer Ther.,
July 1, 2008;
7(7):
1923 - 1930.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Cohen, H. Dadi, E. Shaoul, N. Sharfe, and C. M. Roifman
Cloning and Characterization of a Lymphoid-Specific, Inducible Human Protein Tyrosine Phosphatase, Lyp
Blood,
March 15, 1999;
93(6):
2013 - 2024.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Corazza, Y. Beguin, P. Bergmann, M. Andre, A. Ferster, C. Devalck, P. Fondu, M. Buyse, and E. Sariban
Anemia in Children With Cancer Is Associated With Decreased Erythropoietic Activity and Not With Inadequate Erythropoietin Production
Blood,
September 1, 1998;
92(5):
1793 - 1798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
